Antipyretic Analgesics and Intermediates

Custom Synthesis, China has become the world’s largest producer of antipyretic and analgesic drugs, aspirin, paracetamol, Ann is nearly three varieties of the production of super million tons, non-butyl, ammonia Kibilin, Bilin production of more than 1000 tons, ibuprofen, inflammatory pain, anti-inflammatory pain, phenylbutazone, methionine, diclofenac, Nepsen, fluorine ketoprofen production of more than 100 tons. For antipyretic analgesics supporting the production of intermediates, large production enterprises.

At the same time, because of the serious pollution of the synthetic process of antipyretic analgesics, the United States and Western Europe are gradually abandoning the production of their raw materials to buy from China, so the production of antipyretic analgesics in China is increasing rapidly, and it is expected to grow at around 8% in the future.

Current situation of pharmaceutical intermediates industry

⑴ production enterprises are mostly private enterprises, flexible operation, small investment, basically in millions of to 10 million or 20 million.

The regional distribution of ⑵ production Enterprises is more concentrated, which is mainly located in Taizhou and Jintan, Jiangsu province.

The ⑶ countries pay more and more attention to environmental issues, which requires manufacturers to build environmentally friendly treatment facilities, which will put a lot of pressure on private enterprises with small production size.

One of the most important characteristics of ⑷ pharmaceutical intermediates is that the rate of production and renewal is fast, and generally 3-5 years later, the profit margin will decrease greatly. This forces companies to constantly develop new products or continuously improve production processes in order to maintain a higher production profit.

⑸ because the production profit of pharmaceutical intermediates is higher than that of chemical products, the production process of both is basically the same, so there are more and more small chemical enterprises to join the production of pharmaceutical intermediates, resulting in the industry disorderly competition increasingly fierce.

⑹ production intermediates compared with raw materials, the profit margin is low, while the raw materials and pharmaceutical intermediates production process is the same, therefore, some enterprises have not only the production of intermediates, but the use of their own advantages, began to produce APIs. Some experts pointed out that the production of pharmaceutical intermediates in the direction of the development of APIs will be an inevitable trend.